公司概述
ImageneBio, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company functions within the healthcare sector, specifically focusing on the biotechnology industry, where value is derived from the potential clinical success of its pipeline candidates. ImageneBio maintains a market capitalization of $53.13 million and employs a workforce of 15 individuals. Its trailing twelve-month revenue stands at $800,000, indicating a very small revenue base relative to its market valuation. The combination of a $53.13 million market cap and minimal annual revenue suggests that the company's current valuation is heavily dependent on future clinical milestones rather than existing cash flows, placing it in the speculative early-stage biotechnology category.
财务健康
ImageneBio, Inc. reported revenue of $800,000 over the trailing twelve months, yet this generated a net income of $-52,395,000, revealing a cost structure where expenses significantly outpace top-line growth. The company's EBITDA was $-48,052,000, further highlighting the substantial cash burn associated with clinical-stage drug development activities. Free cash flow amounted to $-18,874,876, which indicates that the company is currently burning cash and lacks the operational flexibility to fund growth without external capital raises. The gross margin stands at 100.0%, reflecting typical biotechnology cost structures where manufacturing costs are low relative to revenue in early commercial stages, while the operating margin of -6056.4% and profit margin of 0.0% illustrate the intense expense environment typical of pre-revenue biotech firms. The company holds $135.35 million in cash against $2.98 million in debt, creating a substantial liquidity buffer, though the debt-to-equity ratio of 2.23 indicates a levered balance sheet relative to its equity base. A current ratio of 12.49 demonstrates exceptionally strong short-term liquidity, suggesting the company can easily meet its obligations due to its large cash reserves. Return on equity is -68.9% and return on assets is -35.9%, metrics that reveal that management effectiveness is currently measured by capital preservation and the ability to de-risk the pipeline rather than generating immediate profitability.
估值评估
The trailing P/E ratio is not available (N/A) due to negative earnings, while the forward P/E is -1.41, a metric that implies earnings are expected to remain negative in the near future. The price-to-book ratio is 0.40, indicating that the market values the company at a significant discount to its net asset value, which often occurs in biotech firms with high intangible assets or significant cash balances. The price-to-sales ratio is 66.41, a high multiple that suggests investors are pricing in substantial future growth potential despite current low sales, while the EV/EBITDA of 1.65 reflects a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization. The 52-week high is $18.00 and the 52-week low is $3.94, meaning the current price sits within a wide trading range that reflects high volatility and uncertainty surrounding the company's development progress. The beta value is not available (N/A), so the precise correlation of price volatility relative to the broader market cannot be quantified from current data.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available (N/A) due to the lack of historical comparable data or negative earnings, making it impossible to determine if earnings are growing faster or slower than revenue in a traditional sense. ImageneBio, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and cash reserves into research, development, and clinical trials rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company prioritizes capital allocation toward pipeline advancement over returning capital to investors. Consequently, the overall growth and income profile is characterized by zero current income distribution and undefined historical growth rates, relying entirely on the potential future value of its lead product candidate, IMG-007.